共查询到20条相似文献,搜索用时 62 毫秒
1.
目的探讨含利妥昔单抗化疗方案治疗套细胞淋巴瘤(MCL)患者效果及预后影响因素。方法回顾性分析2007年6月至2018年11月苏州大学附属第一医院血液科收治的56例≤65岁MCL患者临床资料,化疗方案中均包括利妥昔单抗,观察临床特征、治疗方案及生物学指标对总生存(OS)和无进展生存(PFS)的影响。结果56例患者中位发病年龄57岁,男性43例,女性13例。24例接受R-CHOP方案化疗;29例接受含阿糖胞苷方案化疗,其中15例接受R-hyper CVAD/R-MA方案化疗,14例接受R-CHOP/R-DAHP交替治疗;3例接受其他方案化疗。19例接受自体造血干细胞移植(ASCT)巩固治疗。56例患者中位OS时间74个月,2年OS率83.8%,3年OS率70.9%,2年PFS率72.0%,3年PFS率49.7%。国际预后指数(IPI)评分和治疗中是否接受ASCT是MCL患者OS和PFS的独立影响因素。含阿糖胞苷治疗组总有效率(ORR)93.1%,优于R-CHOP方案组(83.3%),差异无统计学意义(χ2=0.465,P=0.495);两组间OS及PFS差异均无统计学意义(OS:χ2=0.291,P=0.590;PFS:χ2=0.912,P=0.339)。诱导化疗达缓解的MCL患者中,ASCT巩固治疗可延长中位OS时间(72个月比124个月,χ2=3.973,P=0.040)及中位PFS时间(34个月比90个月,χ2=3.984,P=0.046)。简化MCL国际预后指数(sMIPI)评分中高危组患者中接受ASCT巩固治疗患者OS和PFS优于未接受ASCT治疗者(OS:χ2=5.037,P=0.025;PFS:χ2=6.787,P=0.009),而sMIPI评分低危组患者中,是否接受ASCT组间OS、PFS差异均无统计学意义(均P>0.05)。结论含阿糖胞苷的化疗方案对改善MCL患者的预后和生存并不理想。对于诱导化疗达缓解及sMIPI评分中高危组的MCL患者,ASCT巩固治疗可改善其预后,可作为年轻患者的一线巩固治疗方案。 相似文献
2.
Georg Lenz Martin Dreyling Eva Hoster Bernhard W?rmann Ulrich Dührsen Bernd Metzner Hartmut Eimermacher Andreas Neubauer Hannes Wandt Hjalmar Steinhauer Sonja Martin Else Heidemann Ali Aldaoud Reza Parwaresch Joerg Hasford Michael Unterhalt Wolfgang Hiddemann 《Journal of clinical oncology》2005,23(9):1984-1992
PURPOSE: Mantle cell lymphoma (MCL) is characterized by a poor prognosis with a low to moderate sensitivity to chemotherapy and a median survival of only 3 to 4 years. In an attempt to improve outcome, the German Low Grade Lymphoma Study Group (GLSG) initiated a randomized trial comparing the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and rituximab (R-CHOP) with CHOP alone as first-line therapy for advanced-stage MCL. PATIENTS AND METHODS: One hundred twenty-two previously untreated patients with advanced-stage MCL were randomly assigned to six cycles of CHOP (n = 60) or R-CHOP (n = 62). Patients up to 65 years of age achieving a partial or complete remission underwent a second randomization to either myeloablative radiochemotherapy followed by autologous stem-cell transplantation or interferon alfa maintenance (IFNalpha). All patients older than 65 years received IFNalpha maintenance. RESULTS: R-CHOP was significantly superior to CHOP in terms of overall response rate (94% v 75%; P = .0054), complete remission rate (34% v 7%; P = .00024), and time to treatment failure (TTF; median, 21 v 14 months; P = .0131). No differences were observed for progression-free survival. Toxicity was acceptable, with no major differences between the two therapeutic groups. CONCLUSION: The combined immunochemotherapy with R-CHOP resulted in a significantly higher response rate and a prolongation of the TTF as compared with chemotherapy alone. Hence, R-CHOP may serve as a new baseline regimen for advanced stage MCL, but needs to be further improved by novel strategies in remission. 相似文献
3.
4.
目的:观察重组人粒-巨噬细胞集落刺激因子(rhGM-CSF)联合R-CHOP方案治疗初治弥漫大B细胞淋巴瘤的临床效果及安全性。方法:回顾性分析2017年2月至2019年11月海军军医大学(第二军医大学)长海医院39例接受rhGM-CSF联合R-CHOP方案及39例接受R-CHOP方案治疗的初治DLBCL患者的临床资料,比较两组患者的总反应率(ORR)、完全缓解(CR)率、总生存(OS)、无进展生存(PFS)及不良反应发生情况。结果:rhGM-CSF联合R-CHOP方案组及R-CHOP方案组的ORR分别为87.2%(34/39)、82.1%(32/39),差异无统计学意义(
χ2=0.394,
P=0.53),CR率分别为71.8%(28/39)、56.4%(22/39),差异亦无统计学意义(
χ2=2.006,
P=0.157)。随访截至2020年9月19日,rhGM-CSF联合R-CHOP方案组生存32例,死亡7例,其中1例死于肠癌,原发病仍处于CR状态;R-CHOP方案组生存32例,死亡7例。rhGM-CSF联合R-CHOP方案组及R-CHOP方案组2年OS率分别为82.5%、73.9%(
χ2=0.038,
P=0.845),2年PFS率分别为67.1%、55.2%(
χ2=0.457,
P=0.499)。亚组分析结果显示,rhGM-CSF联合R-CHOP方案组及R-CHOP方案组的生发中心B细胞型亚组间、非生发中心B细胞型亚组间、Lugano分期Ⅰ~Ⅱ期亚组间、Lugano分期Ⅲ~Ⅳ期亚组间、年龄<60岁亚组间、年龄≥60岁亚组间CR率分别比较,差异均无统计学意义(均
P>0.05)。主要不良反应为骨髓抑制及其所致感染,两组3~4级血液学不良反应及感染发生率比较,差异均无统计学意义(均
P>0.05)。予支持治疗后,所有患者均安全度过骨髓抑制期,无治疗相关死亡。
结论:rhGM-CSF联合R-CHOP方案用于初治DLBCL患者安全有效。 相似文献
5.
目的:研究套细胞淋巴瘤(MCL)患者的临床特点及预后相关因素,进一步全面评估病情,探索个体化治疗。方法:回顾性分析2012年1 月至2016年12 月经我院病理科确诊的51例MCL 患者的临床特点、住院20例患者的预后分层和不同化疗方案的近期及远期疗效,并进行随访观察。结果:20例住院治疗患者中,R-Hyper-CVAD组及R-CHOP样组的ORR(分别为100%、100%)均高于其未联合美罗华组(分别为50%、40%);MIPI评分中,低危组ORR为75.0%,明显高于中危组(16.6%);CD5-患者CR、PR均高于CD5+患者;Ki67≥30%患者CR率(20%)大于Ki67<30%组(11%),PR率则相反;Ki67<30%患者3年OS明显高于Ki67≥30%患者,有统计学差异,而PFS无统计学差异;MIPI分组中,低危组3年OS明显高于中高危组,有统计学差异,PFS无统计学差异;美罗华组无论OS还是PFS均高于非美罗华组;Hyper-CVAD组与非Hyper-CVAD组OS、PFS均无统计学差异。结论:美罗华联合化疗治疗MCL的疗效是肯定的,绝大多数患者能够耐受减低剂量的Hyper-CVAD A及B方案化疗,但统计学显示与非Hyper-CVAD组无明显差异,可能与病例数偏少相关,需要更多大样本的循证医学的支持。 相似文献
6.
Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma with a 5-year survival rate of 35%-60%. Various clinical factors included in the International Prognostic Index have failed to identify the patients with DLBCL who will not benefit from the standard R-CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone plus rituximab) treatment regimen. Bcl-2 has been implicated in conferring resistance to chemotherapy in non-Hodgkin's lymphoma and is therefore a candidate prognostic marker in DLBCL. To identify the correlation between Bcl-2 expression and response to rituximab-containing treatment regimens, histologic materials were analyzed from 292 elderly patients with confirmed DLBCL. Of these, 155 patients had received R-CHOP (53%) and 137 had received CHOP (47%). One hundred ninety-three patients (66%) were found to express high levels of Bcl-2 protein in > 50% of the tumor cells. Of the 193 Bcl-2-positive patients, the patients who received R-CHOP had a better 5-year overall rate than patients treated with CHOP (56% vs. 42%; P = 0.01), whereas in the patients with Bcl-2-negative disease, there was no statistically significant difference in the 5-year overall survival rates between the R-CHOP and CHOP regimens (58% vs. 52%; P = 0.6). Therefore, the addition of rituximab to the standard chemotherapy regimen seems to have overcome the Bcl-2-associated resistance to chemotherapy. 相似文献
7.
《Clinical lymphoma & myeloma》2005,6(6):455-457
Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma with a 5-year survival rate of 35%–60%. Various clinical factors included in the International Prognostic Index have failed to identify the patients with DLBCL who will not benefit from the standard R-CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone plus rituximab) treatment regimen. Bcl-2 has been implicated in conferring resistance to chemotherapy in non-Hodgkin's lymphoma and is therefore a candidate prognostic marker in DLBCL. To identify the correlation between Bcl-2 expression and response to rituximabcontaining treatment regimens, histologic materials were analyzed from 292 elderly patients with confirmed DLBCL. Of these, 155 patients had received R-CHOP (53%) and 137 had received CHOP (47%). One hundred ninety-three patients (66%) were found to express high levels of Bcl-2 protein in > 50% of the tumor cells. Of the 193 Bcl-2-positive patients, the patients who received R-CHOP had a better 5-year overall rate than patients treated with CHOP (56% vs. 42%; P = 0.01), whereas in the patients with Bcl-2-negative disease, there was no statistically significant difference in the 5-year overall survival rates between the R-CHOP and CHOP regimens (58% vs. 52%; P = 0.6). Therefore, the addition of rituximab to the standard chemotherapy regimen seems to have overcome the Bcl-2-associated resistance to chemotherapy. 相似文献
8.
目的 探讨GDP方案治疗复发难治性非霍奇金淋巴瘤的疗效.方法 回顾性分析2009年1月至2014年6月北京大学第三医院收治的40例复发难治性非霍奇金淋巴瘤患者的临床资料,所有患者接受GDP方案(吉西他滨、地塞米松、顺铂)治疗.对患者临床特征及实验室指标进行分析,同时进行生存分析.结果40例患者的治疗总有效率为67.5%(27/40),完全缓解率为27.5%(11/40),部分缓解率为40.0%(16/40),3年总生存(OS)率为86.5%,5年OS率为28.8%.B细胞淋巴瘤和T细胞淋巴瘤治疗总有效率分别为69.6%(16/23)、52.9%(9/17),3年OS率分别为90.9%、80.7%,差异均无统计学意义(P=0.283,P=0.480);胃肠道受累患者治疗完全缓解率优于非胃肠道受累患者,差异有统计学意义(P=0.049),3年OS率略优于非胃肠道受累患者(89.3%比76.2%),但差异无统计学意义(P=0.237).不良反应主要表现为血液系统不良反应,Ⅲ~Ⅳ级粒细胞减少发生率为47.5%(19/40),Ⅲ~Ⅳ级血小板减少发生率为40.0%(16/40),Ⅲ~Ⅳ级贫血发生率为17.5%(7/40);非血液系统不良反应主要表现为轻度恶心、呕吐.结论 GDP方案治疗复发难治性非霍奇金淋巴瘤效果较好,起效快,耐受性好,对胃肠道受累患者疗效更好. 相似文献
9.
Bo Jia Yuankai Shi Suyi Kang Sheng Yang Shaoxuan Hu Yexiong Li Mei Dong Weihu Wang Jianliang Yang Liqiang Zhou Peng Liu Shengyu Zhou Yan Qin Lin Gui Changgong Zhang Hua Lin Shanshan Chen Lin Wang Xiaohui He 《中国癌症研究》2015,27(5):516-523
Background
The role of rituximab in combination with CHOP regimen in patients with stage I diffuse large B-cell lymphoma (DLBCL) remains to be defined. We aimed to compare CHOP plus rituximab (R-CHOP) with CHOP alone and determine the value of radiotherapy in these patients.Methods
Between 2003 and 2009, 140 untreated patients with stage I DLBCL were retrospectively analyzed in this study.Results
Seventy-eight patients were treated in R-CHOP group and 62 in CHOP group. Ninety-one patients received additional radiotherapy at the end of chemotherapy. The different treatment groups were well-balanced with respect to baseline characteristics. Complete response (CR) rate was 77% both in R-CHOP and CHOP groups (P=0.945). After a median follow-up period of 56 months, patients received R-CHOP regimen had similar 5-year progression-free survival (PFS) (76% vs. 85%; log-rank P=0.215) and 5-year overall survival (OS) (90% vs. 96%; log-rank P=0.175) compared with those with CHOP alone. Patients with radiotherapy had significantly increased 5-year PFS compared with those who had chemotherapy alone (86% vs. 71%; log-rank P=0.005). At multivariate analysis, patients who had CR (P=0.008) and received radiotherapy (P=0.003) were significantly associated with superior PFS.Conclusions
CHOP alone could be as effective as R-CHOP regimen and additional radiotherapy would be necessary for stage I or stage I non-bulky DLBCL patients. 相似文献10.
美罗华联合化疗治疗侵袭性B细胞性非霍奇金淋巴瘤的临床分析 总被引:11,自引:0,他引:11
背景与目的:环磷酰胺、阿霉素、长春新碱、强的松即CHOP方案为治疗侵袭性B细胞性非霍奇金淋巴瘤(B-NHL)的基本方案.但疗效仍不尽人意。几项研究表明,美罗华对B-NHL有较好的疗效。本研究旨在了解美罗华联合化疗治疗中国人侵袭性B-NHL的疗效及安全性,分析影响疗效的相关因素。方法:回顾性总结我科采用美罗华单药或联合化疗(美罗华用量为375mg/m^2)对75例侵袭性B-NHL患者的疗效,分析年龄、分期、1PI积分和巨块等因素对疗效的影响。结果:采用美罗华单药治疗的初治患者有效率为83.3%(5/6),完全缓解(CR)率66.7%(4/6);美罗华联合化疔对初治患者有效率为90.7%(CR率67.4%)。分期晚(P=0.046)、血清乳酸脱氢酶(LDH)(P=0.024)增高、难治或复发(P=0.009)及合并巨块(P=0.013)的患者疗效明显较差。无治疗相关性死亡。结论:美罗华单药治疗侵袭性B-NHL有一定疗效。美罗华合并化疗可取得较好疗效。分期晚、血清LDH水平较高、难治或复发及合并巨块者疗效较差。 相似文献
11.
T Igarashi Y Kobayashi M Ogura T Kinoshita T Ohtsu Y Sasaki Y Morishima T Murate M Kasai N Uike M Taniwaki Y Kano K Ohnishi Y Matsuno S Nakamura S Mori Y Ohashi K Tobinai 《Annals of oncology》2002,13(6):928-943
BACKGROUND: The aim of the study was to determine factors affecting the toxicity and efficacy of rituximab monotherapy in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma (MCL). PATIENTS AND METHODS: A total of 90 patients were enrolled and treated with rituximab infusions at 375 mg/m2 once weekly for 4 weeks. Central pathology review revealed that histologically, 81 patients had indolent B-cell lymphoma or MCL: 59 with follicular lymphoma, 17 with MCL, four with marginal zone lymphoma and one with lymphoplasmacytoid lymphoma. Of these, four were ineligible due to violation of other eligibility criteria. Pre-treatment variables affecting toxicities were analyzed for all 90 patients, and those affecting response and progression-free survival (PFS) were analyzed for 77 eligible patients with confirmed indolent B-cell lymphoma or MCL. The relationship between serum rituximab levels and efficacy was also analyzed for 66 eligible patients. RESULTS: Hematological toxicities (grade > or =3) occurred more frequently in females (P <0.05), and thrombocytopenia and leukopenia were more frequent in patients with high lactate dehydrogenase (LDH) levels (P <0.05). Non-hematological toxicities (grade > or =2) were more frequent in patients with extranodal disease or bone marrow involvement. The overall response rate (ORR) in patients receiving one prior chemotherapy regimen was higher than those receiving two or more regimens (P <0.05). The median PFS was shorter in MCL patients, in those with extranodal disease, or in those receiving two or more prior chemotherapy regimens (P <0.01). The PFS intervals of patients with higher serum rituximab levels (> or =70 microg/ml) immediately before the third infusion were longer than in other patients (P <0.01). CONCLUSIONS: Several prognostic factors and serum rituximab levels are useful for predicting the toxicity and efficacy of rituximab monotherapy. 相似文献
12.
Houot R Le Gouill S Ojeda Uribe M Mounier C Courby S Dartigeas C Bouabdallah K Alexis Vigier M Moles MP Tournilhac O Arakelyan N Rodon P El Yamani A Sutton L Fornecker L Assouline D Harousseau JL Maisonneuve H Caulet-Maugendre S Gressin R;French GOELAMS group 《Annals of oncology》2012,23(6):1555-1561
BackgroundThere is no consensual first-line chemotherapy for elderly patients with mantle cell lymphoma (MCL). The GOELAMS (Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang) group previously developed the (R)VAD+C regimen (rituximab, vincristine, doxorubicin, dexamethasone and chlorambucil), which appeared as efficient as R-CHOP (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone) while less toxic. Based on this protocol, we now added bortezomib (RiPAD+C: rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil) given its efficacy in relapsed/refractory MCL patients. The goal of the current phase II trial was to evaluate the feasibility and efficacy of the RiPAD+C regimen as frontline therapy for elderly patients with MCL.Patients and methodsPatients between 65 and 80 years of age with newly diagnosed MCL received up to six cycles of RiPAD+C.ResultsThirty-nine patients were enrolled. Median age was 72 years (65–80). After four cycles of RiPAD+C, the overall response rate was 79%, including 51% complete responses (CRs). After six cycles, CR rate increased up to 59%. After a 27-month follow-up, median progression-free survival (PFS) is 26 months and median overall survival has not been reached. Four patients (10%) discontinued the treatment because of a severe toxicity and seven patients (18%) experienced grade 3 neurotoxicity.ConclusionThe bortezomib-containing RiPAD+C regimen results in high CR rates and prolonged PFS with predictable and manageable toxic effects in elderly patients with MCL. 相似文献
13.
目的 探讨放疗在早期弥漫大B细胞淋巴瘤(DLBCL)化疗后达CR患者中的地位。方法 回顾分析2004—2012年本院治疗的376例Ⅰ、Ⅱ期DLBCL患者资料,均接受至少3个周期CHOP和利妥昔单抗+CHOP方案化疗(R-CHOP)后达CR者。R-CHOP组92例,R-CHOP+放疗组79例,CHOP+放疗组98例,CHOP组107例。放疗为累及野照射30~56 Gy。Kaplan-Meier法计算生存率并Logrank法检验,Cox回归模型多因素预后分析。结果 5年样本量为188例。全组5年DFS、OS分别为80.7%、87.6%,R-CHOP+放疗组和R-CHOP组的分别为94.9%和88.1%(P=0.030)、97.9%和86.0%(P=0.026),CHOP+放疗组和CHOP组的分别为74.2%和71.4%(P=0.623)、87.0%和82.1%(P=0.420)。多因素分析显示吸烟指数<500、IPI<2、加用利妥昔单抗是预后有利因素(P=0.034~0.000)。结论 放疗对早期DLBCL可以提高R-CHOP化疗后CR者的DFS和OS。建议DLBCL使用含利妥昔单抗的化疗,R-CHOP化疗后应接受放疗。希望开展随机对照研究进一步证明该结果。 相似文献
14.
目的 评估神经激肽1(NK1)受体拮抗剂阿瑞匹坦联合泼尼松、托烷司琼预防R-CHOP或CHOP方案化疗所致恶心、呕吐(CINV)的疗效及安全性.方法 选择2015年10月至2016年1月天津市人民医院90例弥漫大B细胞淋巴瘤(DLBCL)患者,接受R-CHOP或CHOP方案治疗.采用随机数字表法分为两组,阿瑞匹坦组45例,于第1天化疗前1 h口服阿瑞匹坦125 mg及泼尼松100 mg,静脉滴注托烷司琼10 mg,化疗后2 h静脉滴注托烷司琼5 mg;第2、3天口服阿瑞匹坦80 mg及泼尼松100 mg,静脉滴注托烷司琼10 mg;第4、5天口服泼尼松100 mg.对照组45例,于第1天化疗前1 h口服泼尼松100 mg,静脉滴注托烷司琼10 mg,化疗后2 h静脉滴注托烷司琼5 mg;第2、3天口服泼尼松100 mg,静脉滴注托烷司琼10 mg;第4、5天口服泼尼松100 mg.每天记录患者CINV发生次数及缓解治疗方法.记录整个周期CINV完全缓解率(无呕吐且未用缓解药物)和整个周期无呕吐率,采用生活功能指数(FILE)问卷评估CINV对患者生命质量的影响.结果阿瑞匹坦组CINV完全缓解率为77.8%(35/45),高于对照组的55.6%(25/45),差异有统计学意义(χ2=5.000,P=0.025);阿瑞匹坦组无呕吐率为82.2%(37/45),高于对照组的62.2%(28/45),差异有统计学意义(χ2=4.486,P=0.034).阿瑞匹坦组和对照组FILE问卷平均得分分别为(113±10)和(100±11)分,差异有统计学意义(t=12.437,P<0.001).两组止吐药物相关不良反应发生率比较,差异均无统计学意义(均P>0.05).结论 阿瑞匹坦联合托烷司琼、泼尼松可有效改善DLBCL患者R-CHOP或CHOP方案化疗所致的恶心、呕吐. 相似文献
15.
Josting A Reiser M Wickramanayake PD Rueffer U Draube A Söhngen D Tesch H Wolf J Diehl V Engert A 《Leukemia & lymphoma》2000,37(1-2):185-187
Mantle-cell lymphoma (MCL) is not a curable disease using conventional chemotherapy. Patients with MCL have the shortest median time to progression and the shortest median survival of all lymphoma subtypes after first-line treatment. In the present study we determined the efficacy of maximal cytoreductive therapy with up to four cycles of Dexa-BEAM (dexamethasone, carmustine [BCNU], etoposide, cytarabine, and melphalan) followed by high-dose chemotherapy (HDCT) and autologous hematopoietic stem cell support (ASCT) for patients with advanced relapsed or refractory MCL. Nine consecutive patients with relapsed or refractory MCL were included. Three patients had partial remission (PR), three patients progressive disease (PD) upon first line tretment, and three patients first or subsequent relapse. After 2 to four cycles of Dexa-BEAM eight patients achieved complete remission (CR), resulting in a response rate of 88%. Six of 8 patients responding to Dexa-BEAM received high-dose chemotherapy HDCT (BEAM) and autologous hematopoietic stem cell transplantation (ASCT). With a median follow up of 24 months six patients are alive. Five of those six patients are still in contiuous CR (range 13-54 months). 相似文献
16.
目的探讨高龄弥漫大B细胞淋巴瘤(DLBCL)患者的临床特征和预后情况。方法回顾性分析2016年1月至2018年12月上海交通大学医学院附属第九人民医院收治的13例高龄(年龄≥75岁)DLBCL患者的临床病理资料,均接受了R-CHOP方案为基础的个体化治疗,观察其临床特征、治疗疗效及预后情况。结果高龄DLBCL患者的中位年龄82岁(范围:75~89岁);69.2%(9/13)的患者Ann Arbor分期为Ⅲ~Ⅳ期;84.6%(11/13)的患者ECOG评分≥2;46.2%(6/13)的患者存在多处淋巴结外器官受累;8例(61.5%)完成了3个周期以上的化疗,客观缓解率(ORR)为15.4%(2/13)。2年无进展生存率为23.1%,2年生存率为53.8%。61.5%(8/13)的患者出现了3级及以上中性粒细胞减少,30.8%(4/13)的患者出现了3级及以上血小板减少;76.9%(10/13)的患者出现了肺部感染。单因素预后分析显示,改良国际预后指数(IPI)评分高、RCHOP方案不足3个周期及合并多种基础疾病者生存率低(P<0.05)。结论高龄DLBCL患者往往表现为侵袭性强、不... 相似文献
17.
18.
R-CHOP与CHOP方案治疗初治弥漫大B细胞型淋巴瘤在中国的多中心随机对照研究 总被引:12,自引:1,他引:11
Lin TY Zhang HY Huang Y Guan ZZ Shen T Shi YK Zhu J Ke XY Wang HQ Shen ZX Yu SY Liu T Shi XL 《癌症》2005,24(12):1421-1426
背景与目的:CHOP化疗方案是目前治疗弥漫性大B细胞型非霍奇金淋巴瘤(non-HodgkinTslymphoma,NHL)的标准方案。利妥昔单抗(美罗华)作为一种针对CD20抗原表达阳性的B细胞的嵌合型单克隆抗体,对弥漫性大B细胞型淋巴瘤具有良好的疗效。在欧洲和美国,利妥昔单抗联合标准化疗方案治疗进展型NHL已经获得批准。本研究旨在比较利妥昔单抗加标准CHOP方案与标准CHOP方案治疗中国人CD20阳性的弥漫大B细胞型NHL患者的疗效和安全性。方法:2003年9月至2004年11月在全国9个研究中心进行,共有63例患者入组,其中CHOP组32例,R-CHOP组31例。所有入组患者均签署并提供知情同意书。CHOP组患者接受每3周为1个疗程共6个疗程的CHOP方案治疗;R-CHOP组患者在每个疗程开始的第1天联用利妥昔单抗的CHOP治疗方案。比较两组的完全缓解率、总体缓解率以及不良反应情况。结果:R-CHOP组和CHOP组的完全缓解率相似(41.9%vs.37.5%,P=0.719),而总体缓解率前者要高于后者(83.8%vs.65.6%,P=0.096),但无显著性差异。治疗期间CHOP组有21.9%的患者疾病进展,而R-CHOP组仅为3.2%,两组有显著性差异(P=0.026)。R-CHOP组和CHOP组的不良反应发生率相似(65.6%vs.67.7%),差异无显著性(P=0.859)。最常见的不良反应均为白细胞下降;R-CHOP组其次常见不良反应是发热和寒战,可能与输注利妥昔单抗有关。两组的临床相关毒副作用相似,差异无显著性。结论:利妥昔单抗联合CHOP方案治疗CD20阳性的弥漫大B细胞型NHL与单纯CHOP方案相比,能显著降低治疗失败率,同时并不增加化疗的毒副反应。 相似文献
19.
目的 评价将R-CHOP方案(利妥昔单抗+环磷酰胺+长春新碱+多柔比星+泼尼松)中的多柔比星改为含聚乙二醇脂质体多柔比星的R-CDOP方案治疗弥漫性大B细胞淋巴瘤患者的疗效和安全性.方法 回顾性收集76例弥漫性大B细胞淋巴瘤患者的临床资料,其中39例使用标准的R-CHOP方案化疗(R-CHOP组),37例使用含多柔比星... 相似文献
20.
目的 探讨弥漫大B细胞性淋巴瘤(DLBCL) 临床病理特点与利妥昔单抗疗效之间的关系.方法 回顾性分析69例采用利妥昔单抗联合化疗治疗DLBCL患者的临床资料,探讨DLBCL临床病理特征对疗效的影响.应用免疫组化SP法检测Bcl-2、survivin及bax蛋白的表达,分析其表达与利妥昔单抗疗效之间的关系.结果 采用利妥昔单抗联合化疗治疗初治DLBCL患者,有效率为90.7%,完全缓解(CR)率为69.8%;难治或复发患者的有效率为80.8%,CR率为30.8%.分期晚(P=0.046)、血清乳酸脱氢酶(LDH)水平较高(P=0.024)、难治或复发(P=0.009)以及合并大肿块(P=0.013)的患者疗效明显差.Bcl-2表达阳性者的疗效明显好于阴性者(P=0.04);bax和survivin的表达则与疗效无关(P>0.05).结论 利妥昔单抗联合化疗治疗DLBCL患者,有效率和CR率较高,且患者耐受性良好.但分期较晚、LDH水平较高、难治或复发、合并大肿块以及Bcl-2表达阴性患者的疗效较差. 相似文献